TY - JOUR
T1 - Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)
AU - Saber, Wael
AU - Cutler, Corey S.
AU - Nakamura, Ryotaro
AU - Zhang, Mei Jie
AU - Atallah, Ehab
AU - Rizzo, J. Douglas
AU - Maziarz, Richard T.
AU - Cortes, Jorge
AU - Kalaycio, Matt E.
AU - Horowitz, Mary M.
PY - 2013/9/12
Y1 - 2013/9/12
N2 - Allogeneic hematopoietic cell transplantation (HCT) from human leukocyte antigen (HLA) matched related donor (MRD) and matched unrelated donors (MUD) produces similar survival for patients with acute myelogenous leukemia.Whether these results can be extended to patientswithmyelodysplastic syndromes (MDS) is unknown. Therefore, analysis of post-HCT outcomes for MDS was performed. Outcomes of 701 adult MDS patients who underwent HCT between 2002 and 2006 were analyzed (MRD [n 5 176], 8 of 8 HLA-A, -B, -C, -DRB1 allele matchedMUD [n 5 413], 7 of 8 MUD [ n 5 112]). Median agewas 53 years (range, 22-78 years). In multivariate analyses, MRD HCT recipients had similar disease free survival (DFS) and survival rates compared with 8 of 8 MUD HCT recipients (relative risk [RR] 1.13 [95% confidence interval (CI) 0.91-1.42] and 1.24 [95% CI 0.98-1.56], respectively), and both MRD and 8 of 8MUD had superior DFS(RR1.47 [95%CI 1.10-1.96] and 1.29 [95%CI 1.00-1.66], respectively) and survival (RR 1.62 [95% CI 1.21-2.17] and 1.30 [95% CI 1.01-1.68], respectively) compared with 7 of 8 MUDHCT recipients. In patients with MDS, MRD remains the best stem cell source followed by 8 of 8 MUD. Transplantation from 7 of 8 MUD is associated with significantly poorer outcomes.
AB - Allogeneic hematopoietic cell transplantation (HCT) from human leukocyte antigen (HLA) matched related donor (MRD) and matched unrelated donors (MUD) produces similar survival for patients with acute myelogenous leukemia.Whether these results can be extended to patientswithmyelodysplastic syndromes (MDS) is unknown. Therefore, analysis of post-HCT outcomes for MDS was performed. Outcomes of 701 adult MDS patients who underwent HCT between 2002 and 2006 were analyzed (MRD [n 5 176], 8 of 8 HLA-A, -B, -C, -DRB1 allele matchedMUD [n 5 413], 7 of 8 MUD [ n 5 112]). Median agewas 53 years (range, 22-78 years). In multivariate analyses, MRD HCT recipients had similar disease free survival (DFS) and survival rates compared with 8 of 8 MUD HCT recipients (relative risk [RR] 1.13 [95% confidence interval (CI) 0.91-1.42] and 1.24 [95% CI 0.98-1.56], respectively), and both MRD and 8 of 8MUD had superior DFS(RR1.47 [95%CI 1.10-1.96] and 1.29 [95%CI 1.00-1.66], respectively) and survival (RR 1.62 [95% CI 1.21-2.17] and 1.30 [95% CI 1.01-1.68], respectively) compared with 7 of 8 MUDHCT recipients. In patients with MDS, MRD remains the best stem cell source followed by 8 of 8 MUD. Transplantation from 7 of 8 MUD is associated with significantly poorer outcomes.
UR - http://www.scopus.com/inward/record.url?scp=84887389178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887389178&partnerID=8YFLogxK
U2 - 10.1182/blood-2013-04-496778
DO - 10.1182/blood-2013-04-496778
M3 - Article
C2 - 23847196
AN - SCOPUS:84887389178
SN - 0006-4971
VL - 122
SP - 1974
EP - 1982
JO - Blood
JF - Blood
IS - 11
ER -